Quantcast

Latest Peptides Stories

2010-07-22 06:30:00

SAN FRANCISCO, July 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointment of Richard B. Brewer as Executive Chairman. With over 35 years of biotech and pharmaceutical industry experience, Mr. Brewer brings a wealth of operational, financial, and business development expertise to Nile. "We are extremely pleased to welcome Mr. Brewer to our...

990ab4b029028b7861d71b79a5ef5f021
2010-06-24 08:44:59

A team of Vanderbilt chemists has developed a novel method for chemically synthesizing peptides that promises to lower the cost and increase the availability of drugs based on natural compounds. The new synthesis technique is described in a paper published in the June 24 issue of the journal Nature. Peptides are polymers made by stringing together two or more amino acids, the chemical building blocks of life, in a linear chain and folded into a globular form. DNA holds the blueprints for 20...

3f3e9302d0bc34c22224d878d923b8881
2010-06-21 14:15:00

In a breakthrough, UCI chemists create synthetic antibodies that block bee venom UC Irvine researchers have developed the first "plastic antibodies" successfully employed in live organisms "“ stopping the spread of bee venom through the bloodstream of mice. Tiny polymeric particles "“ just 1/50,000th the width of a human hair "“ were designed to match and encase melittin, a peptide in bee venom that causes cells to rupture, releasing their contents. Large quantities of...

2010-06-17 08:30:00

BASKING RIDGE, N.J., June 17 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 2010 Wells Fargo Healthcare Conference at the InterContinental Hotel in Boston, Massachusetts. Dr. Mazzo's presentation will be given at 8:00 am (EDT) on Thursday, June 24 in the Robinson Room and will include an overview of the Company's...

8269a8b716b8ce9ff22b7288634702d01
2010-06-09 10:28:10

Scientists are reporting the first evidence that a plastic antibody "” an artificial version of the proteins produced by the body's immune system to recognize and fight infections and foreign substances "” works in the bloodstream of a living animal. The discovery, they suggest in a report in the Journal of the American Chemical Society, is an advance toward medical use of simple plastic particles custom tailored to fight an array of troublesome "antigens." Those antigens include...

2010-06-08 08:30:00

BASKING RIDGE, N.J., June 8 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Jefferies 2010 Global Life Sciences Conference in New York City held June 8-11, 2010. At this invitation-only event, Dr. Mazzo's presentation will be given at 1:15 pm (EDT) on Friday, June 11 in Track E and will include an overview of the...

2010-06-07 08:30:00

BASKING RIDGE, N.J., June 7 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 9th Annual Needham Healthcare Conference at the New York Palace Hotel in New York City. Dr. Mazzo's presentation will be given at 10:40am (EDT) on Thursday, June 10 in the Chairman's Office and will include an overview of the Company's pipeline...

2010-05-25 08:30:00

BASKING RIDGE, N.J., May 25 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced issuance of another key patent related to their proprietary technology. This new patent includes coverage for RB007, the modulator or active control component of Regado's innovative product candidates, the REG1 and REG2 anticoagulation systems. The allowed claims in U.S. Patent No. 7,723,315 broadly...

2010-05-11 08:03:00

CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 13, 2010, which will include discussion of the results of operations in greater detail and an update on corporate developments. Schedule for the...

2010-05-04 06:30:00

CRANBURY, N.J., May 4 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors. Palatin has received Notices of Allowance from the U.S. Patent and Trademark Office on four additional patent applications relating to...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related